E-mail: pirverdiaygün@mail.ru
39
J, 2016, 3, 39-44
Quliyev F. .
RAD KAL PROSTATEKTOM YADAN SONRA B OK MY V RES D V N
NK AFINDA ÜÇÜNCÜLÜ QL SON NDEKS N N PROQNOST K H M YY T
Milli Onkologiya M rk zi, Bak
Xülas . M qal d radikal prostatektomiyadan sonra biokimy vi residivin m l g lm sind v tezliyind
üçüncülü Qlison indeksinin h miyy tini öyr nm k m qs dil apar lm t dqiqat i i haqq nda m lumat
verilir.
T dqiqat material n iyul 2001-ci ild n oktyabr 2015-ci il d k üz rind aç q radikal prostatektomiya
keçirilmi 265 x st t kil edib. X st l rin orta ya h ddi 61,5±0,4 (mediana 62, diapazon 44-76) t kil edib.
Üçüncülü Qlison indeksinin 4 v daha art q olmas 29 (10,9%) x st d t sdiql nib. Biokimy vi residivi
olan 49 x st d n 14-nün (28,6%) patomorfoloji müayin sind üçüncülü Qlison indeksi qeyd al nm d r.
Üçüncülü Qlison indeksi v biokimy vi residiv aras nda münt z m statistik laq a kar edilmi dir
( 2=19,17; p<0,001).
Al nan n tic l r üçüncülü Qlison indeksinin radikal prostatektomiyadan sonrak biokimy vi residivin
inki af nda proqnostik faktor kimi h miyy tini t sdiql yir.
Açar sözl r: üçüncülü Qlison indeksi, biokimy vi residiv, radikal prostatektomiya
:
,
,
-
Keywords: tertiary Gleason pattern, biochemical recurrence, radical prostatectomy
. .
,
,
.
265
,
,
2001
2015 .
61,5±0,4 (
62,
44-76)
.
4
29 (10,9%)
. 14 (28,%) 49
.
( 2=19,17; p<0,001).
-
.
-
-
(
)
.
-
-
-
-
.
-
40
.
(
)
-
-
[1].
“
”
“
”
-
,
-
,
.
-
-
,
,
-
.
(
).
.
-
265
,
,
2001
2015
.
61,5±0,4 (
62,
44-76)
.
-
.
-
-
.
(
)
9,86±0,45
(
7,64,
1,71-49,30) /
.
-
.
-
,
146
(55,2%)
1
.
2
,
2b
2
-
35 (13,2%), 51 (19,2%) 17 (6,4%) -
.
-
-
9 (3,4%)
3
, 7 (2,6%)
T
3b
.
-
65 (24,5%)
. 54 (20,4%)
-
.
-
-
.
-
-
[2, 3].
-
TNM 2009
[4].
0,2 /
[5].
-
.
-
SPSS 18.0 for
Windows.
-
t-
-
.
-
.
-
-
-
(Log Rank test).
<0,05.
.
-
146 (55,1%)
-
6
.
3+4
4+3
-
72 (27,2%) 22 (8,3%) -
. 17 (6,4%) -
8,
8 (3%)
9
.
4
29 (10,9%)
-
<5%
.
20,3±1,2% (
15,
1-90).
-
48 (18,1%),
31 (11,7%)
.
-
62 (23,4%)
.
-
-
21,3±0,8 (
-
20,
14-51). 9
-
41
.
-
53,3±2,4
(
42,
12-166).
-
49 (18,5%)
.
14
.
-
-
-
1 2.
-
.
-
6, 3+4, 4+3 8-10
16 (32,6%), 11
(22,4%), 4 (8,2%) 4 (8,2%)
.
,
7 (14,3%)
-
6
. 4
(8,2%) 3 (6,1%)
-
-
3+4 4+3
-
.
-
14 (28,6%)
-
.
9 (18,4%) 12 (24,5%) -
.
-
,
3 (6,1%)
,
6 (12,2%)
. 5 (10,2%)
.
-
.
-
-
( 2=19,17; p<0,001).
-
(p<0,001).
1.
, (%)
35 (71,4)
14 (28,6)
-
(
) 63,3±0,96
61,6±1,6
0,426
, ( /
) 11,7±1,44
13,9±3,1
0,446
, ( /
) 1,8±0,2
2,4±0,7
0,337
/
, (%)
19,5±2,6
25,4±8,1
0,365
, ( /
2
) 0,29±0,05
0,35±0,06
0,423
2.
, (%)
35 (71,4)
14 (28,6)
-
, (%)
27,9±3,6
30,1±6,0
0,741
15,0±1,3
17,4±2,1
0,304
1,7±0,5
3,7±1,5
0,212
, (
.) 73,4±8,2
53,8±11,3
0,193
, (
.)
28,8±3,7
17,7±3,9
0,041
42
28,8±3,7
(95%
: 21,5-36,1) 24,0±3,5
(95%
: 17,1-30,9)
.
-
-
,
17,7±3,9
(95%
: 9,9-25,5)
15,0±1,1
(95%
: 12,9-17,1)
-
.
,
-
,
Log Rank
(p=0.041).
-
1.
1.
.
-
,
-
-
,
-
-
[6, 7].
,
-
-
-
,
.
-
,
,
[8].
“
-
” “
”
-
-
-
.
43
.
-
,
-
.
-
,
-
-
22,5% [9].
-
-
.
.
,
, Servoll
.
-
( =0,006).
7
-
-
(
4,03, 95%
1,72-9,46;
= 0,001) [10].
, Adam
.
-
-
-
-
.
-
-
(p<0,001) [11].
-
10,9%.
-
,
.
-
-
-
.
-
-
,
-
.
,
-
-
-
4 5.
,
-
.
,
,
-
-
.
.
-
-
.
-
.
1. Gleason D.F. Classification of prostatic carcinomas // Cancer Chemother Rep. 1966 Mar;50(3):125-8.
2. Egevad L., Delahunt B., Srigley J.R., Samaratunga H. International Society of Urological Pathology (ISUP)
grading of prostate cancer- An ISUP consensus on contemporary grading // APMIS. 2016 Jun;124(6):433-5.
3. Epstein J.I., Allsbrook W.C. Jr, Amin M.B. et al. The 2005 International Society of Urological Pathology
(ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma // Am J Surg Pathol. 2005
Sep;29(9):1228-42.
4. Sobin L.H., Gospodariwicz M., Wittekind C. TNM classification of malignant tumors // UICC International Union
Against Cancer. Wiley-Blackwell, 2009 Dec; pp. 243-248.
5. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer // Eur Urol. 2014 Jan;65(1):124-
37.
6. Aguilera A., Bañuelos B., Díez J. et al. Biochemical recurrence risk factors in surgically treated high and very high-
risk prostate tumors // Cent European J Urol. 2015;68(3):302-7.
44
7. Koca O., Ün S., Türk H., Zorlu F. The factors predicting biochemical recurrence in patients with radical
prostatectomy // Arch Ital Urol Androl. 2016 Jan 14;87(4):270-5.
8. Nguyen T., Boldt R.G., Rodrigues G. Prognostic Factors for Prostate Cancer Endpoints Following Biochemical
Failure: A Review of the Literature // Cureus. 2015 Jan 5;7(1):e238.
9. Isbarn H., Ahyai S.A., Chun F. et al. Prevalence of tertiary Gleason grade and its impact on adverse histopathologic
parameters in a contemporary radical prostatectomy series // Eur Urol 2009;55:394–403.
10. Servoll E.,
Saeter T.,
Vlatkovic L. et al. Impact
of a
tertiary
Gleason
pattern
4
or
5 in clinical failure
and mortality after radical
prostatectomy for clinically localised prostate cancer // BJU Int. 2012 May;109(10):1489-94.
11. Adam M., Hannah A., Budäus L. et al. A tertiary Gleason pattern in the prostatectomy specimen and its association
with adverse outcome after radical prostatectomy // J Urol. 2014 Jul;192(1):97-101.
Guliyev F.A.
The prognostic value of a tertiary Gleason pattern in the development
of biochemical recurrence after radical prostatectomy
National Center of Oncology, Baku
Summary. The article presents the results of a study conducted with aim to
evaluate the incidence and
influence of tertiary Gleason score on biochemical recurrence after radical prostatectomy.
The performed study included 265 patients who underwent open radical prostatectomy between July 2001
and October 2015. The average age of the patients was 61,5±0,4 (median 62, range 44-76) years.
Tertiary Gleason score 4 was diagnosed in 29 (10,9%) patients. The histological evaluation revealed the
presence of a tertiary Gleason pattern in 14 (28,6%) of 49 patients with biochemical recurrence. The
correlation analysis between tertiary Gleason pattern and biochemical recurrence demonstrated statistical
significance ( 2 = 19,17; p <0,001).
These results confirm the importance of a tertiary Gleason pattern as a prognostic factor in the
development of biochemical recurrence after radical prostatectomy.
R yçi: biol.e.d., prof. A.M. f ndiyev
drfuad@mail.ru
45
J, 2016, 3, 45-52
Qurbanov Y.Z., Abbasova M.R., Rzayeva R. ., Novruzova M.S.
2-ci T P
K RL D ABET OLAN V OLMAYAN X ST L RD ÜMUM YUXU
ARTER YASI HÖVZ S DAMARLARININ ENDOTEL D SFUNKS YASININ
NK AFINDA HOMOS STE N N ROLU V BU ZAMAN ÜR Y N EM K
X ST L Y N N NK AF R SK
Az rbaycan Tibb Universitetinin Terapevtik v pediatrik propedevtika kafedras , Bak
Xülas . M qal d 2-ci tip k rli diabeti olan v olmayan x st l rd ümumi, xarici v daxili yuxu
arteriyalar n n morfo-funksional v ziyy ti il homosistein mübadil si, endotelin damar-h r ki v hasilat
aktivliyinin s m r liliyi v ür yin i emik x st liyinin lam tl ri (EKQ-nin Holter monitoriqi zaman ST
seqmentinin patoloj d yi m l rinin qiym tl ndirilm si sas nda)aras nda mövcud olan laq l rin xüsusiy-
y tl ri t qdim olunmu dur.
Göst rilmi dir ki, k rli diabet x st l rind , xüsusil x st liyin arterial hipertneziya il mü ayi t edildiyi
hallarda, endotelin damar-h r ki v hasiledici funksiyalar ciddi pozulur. Qeyd edilmi d yi iklikl r qan
plazmas nda homosisteinin konsentrasiyas ndan as l olmaqla yana , endotelin disfunksiyas il homosistein
mübadil sinin pozulmas mü ahid edil n pasiyentl rd ür yin i emik x st liyinin lam tl rin daha çox rast
g linmi dir. Bel likl , 2-ci tip k rli diabet x st l rind , xüsusil arterial t zyiqin v qan plazmas nda
homosisteinin s viyy l rinin yüks lm si il mü ayi t edildiyi hallarda endotelin funksiyas n n pozulmas n
n n vi farmakoloj müalic y lav olaraq adekvat d rman t yini t l b ed n gizli koronar çat mazl n
qeyri-q na tb x proqnostik markerl rind n biri kimi q bul etm k olar.
Açar sözl r: 2-ci tip k rli diabet, arterial hipertenziya, endotel qi an n disfunksiyas , homosistein
:
2
,
,
,
Key words: diabetes mellitus type 2, arterial hypertension, endothelium dysfunction, homocysteine
. .,
. .,
. .,
. .
A
2
, .
-
-
,
,
,
-
(
ST
)
2
.
,
-2
,
.
-
,
-
.
,
-
2
,
-
,
,
.
46
,
-
2-
(
-2),
[1-3].
-
-
-
,
-
[4; 5].
,
,
-
[6-8].
-
-
,
-
,
(
) [9-
10
]
,
-
-2,
-
-
-
. [11; 12].
-
-
,
.
,
,
-
-
-
,
-
(
)
-
-
-
-2
.
.
-
-
159
: 101 (63,52%)
58 (36,48%)
,
27
81
59,22 + 8,66
.
-
-
,
,
,
,
(
-
,
)
-
[13],
-
-2
(
).
-
-1 ( -1)
-
-
IMMULITE 2000 XPi
“SIEMENS”.
2
-2:
1- 73
(49
24
)
-2;
2 -
(
) – 86
(52
34
)
-2.
-2
-
(
)
-
(
)
2
[14].
-2 32
(20,12%)
, 41
(25,79%)
-
. 49
(30,82%)
-2
-
, 24 (15,09%) -
.
(
)
-
-
[14].
(
)
( = 0,3),
(
= 0,2).
-
:
(
);
I-II (
-
)
;
(
);
(
)
(
).
,
,
-
-
-
(
)
(
) II-III
-
(
)
-2,
(
1).
-
(
–
(
),
(
),
-
(
)
(
)
-
).
-
PHILIPS-HD 11 (
)
-
7,5
Dostları ilə paylaş: |